[Clinical and experimental study on effect of Chanbei Kechuanping in treating bronchial asthma]

To observe the clinical effect of Chanbei Kechuanping (CBKCP) on bronchial asthma and to explore its mechanism.

Ninety-six patients of bronchial asthma were randomly divided into two groups, the CBKCP treated group and the control group (treated by Guilong Kechuanning). The changes on symptoms and signs of asthma, pulmonary function, T-lymphocyte subsets, plasma soluble interleukin-2 receptor (sIL-2R), thromboxane B2(TXB2) and 6-keto-prostaglandin F1 alpha(6-keto-PGF1 alpha) were observed before and after treatment.

(1) The markedly effective rate and effective rate in the CBKCP treated group were higher than those in the control group. The pulmonary function, including 1 second forced expiratory volume, maximum expiratory flow rate and forced lung expiratory vital capacity were all improved in both groups, but the effect was more obvious in the CBKCP treated group. (2) As compared with the control group, CBKCP showed more obvious effect in lowering sIL-2R, T-lymphocyte subset and raising 6-keto-PGF1 alpha. Experimental study of guinea pig with asthma model showed that CBKCP could markedly prolong the latent time of asthma attack, lower the percentage of mast cells in total cells in the alveoli lavage solution, blood acidophic cell count and degranulation rate of mast cells, and decrease IgE, IL-4 and TXB2 levels as well as increase the 6-keto-PGF1 alpha level.

CBKCP has favorable therapeutic effect on asthma attack, it might play the role partly by regulating the functional T-lymphocyte subsets, reducing the level of IgE, sIL-2R, IL-4 and TXB2, and increasing the level of 6-keto-PGF1 alpha.